US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
Can-Fite BioPharma (NYSE American: CANF) announced that its lead drug candidate Namodenoson has been granted a US patent for use as an anti-obesity drug. The patent (No. 17/309,952), expiring in 2042, covers methods of treating obese patients with oral Namodenoson.
The drug demonstrated effectiveness by reducing fat levels through increased adiponectin hormone production and showed weight reduction in animal obesity models. In a Phase IIa MASH study, patients treated with Namodenoson experienced a 2.3% weight loss after 3 months with significant adiponectin level increases.
Namodenoson is currently in Phase IIb trials for MASH treatment, where most patients are obese. The global obesity treatment industry is projected to reach $60.5 billion by 2030, with an expected compound annual growth rate of 22.3% from 2025-2030.
Can-Fite BioPharma (NYSE American: CANF) ha annunciato che il suo principale candidato farmaceutico Namodenoson ha ottenuto un brevetto statunitense per l'uso come farmaco anti-obesità. Il brevetto (No. 17/309,952), che scadrà nel 2042, copre i metodi di trattamento dei pazienti obesi con Namodenoson orale.
Il farmaco ha dimostrato efficacia riducendo i livelli di grasso attraverso un aumento della produzione dell'ormone adiponectina e ha mostrato una riduzione del peso nei modelli animali di obesità. In uno studio di fase IIa MASH, i pazienti trattati con Namodenoson hanno registrato una perdita di peso del 2,3% dopo 3 mesi con significativi aumenti dei livelli di adiponectina.
Namodenoson è attualmente in fase IIb di sperimentazione per il trattamento della MASH, dove la maggior parte dei pazienti è obesa. Si prevede che l'industria globale del trattamento dell'obesità raggiunga 60,5 miliardi di dollari entro il 2030, con un tasso di crescita annuale composto previsto del 22,3% dal 2025 al 2030.
Can-Fite BioPharma (NYSE American: CANF) anunció que su principal candidato a fármaco Namodenoson ha recibido una patente de EE. UU. para su uso como medicamento antiobesidad. La patente (No. 17/309,952), que expira en 2042, cubre métodos para tratar pacientes obesos con Namodenoson oral.
El fármaco demostró efectividad al reducir los niveles de grasa mediante un aumento en la producción de la hormona adiponectina y mostró reducción de peso en modelos de obesidad animal. En un estudio de fase IIa MASH, los pacientes tratados con Namodenoson experimentaron una pérdida de peso del 2.3% después de 3 meses con incrementos significativos en los niveles de adiponectina.
Namodenoson se encuentra actualmente en ensayos de fase IIb para el tratamiento de la MASH, donde la mayoría de los pacientes son obesos. Se proyecta que la industria global del tratamiento de la obesidad alcance $60.5 mil millones para 2030, con una tasa de crecimiento anual compuesta esperada del 22.3% desde 2025 hasta 2030.
Can-Fite BioPharma (NYSE American: CANF)는 주요 약물 후보인 Namodenoson이 비만 치료제로서 미국 특허를 취득했다고 발표했습니다. 이 특허(번호 17/309,952)는 2042년에 만료되며, 경구용 Namodenoson으로 비만 환자를 치료하는 방법을 포함합니다.
이 약물은 아디포넥틴 호르몬 생산 증가를 통해 지방 수치를 감소시키는 효과를 입증했으며, 동물 비만 모델에서 체중 감소 효과를 나타냈습니다. MASH 2a 단계 연구에서 Namodenoson으로 치료받은 환자들은 3개월 후 체중 2.3% 감소를 경험했으며, 아디포넥틴 수치도 크게 증가했습니다.
Namodenoson은 현재 비만 환자가 대부분인 MASH 치료를 위한 2b 단계 시험에 있습니다. 전 세계 비만 치료 산업은 2030년까지 605억 달러에 이를 것으로 예상되며, 2025년부터 2030년까지 22.3%의 연평균 성장률이 예상됩니다.
Can-Fite BioPharma (NYSE American: CANF) a annoncé que son principal candidat médicament Namodenoson a obtenu un brevet américain pour son utilisation comme médicament anti-obésité. Le brevet (n° 17/309,952), qui expira en 2042, couvre les méthodes de traitement des patients obèses avec Namodenoson par voie orale.
Le médicament a démontré son efficacité en réduisant les niveaux de graisse grâce à une augmentation de la production de l'hormone adiponectine et a montré une réduction du poids dans des modèles animaux d'obésité. Dans une étude de phase IIa MASH, les patients traités avec Namodenoson ont enregistré une perte de poids de 2,3% après 3 mois avec des augmentations significatives des niveaux d'adiponectine.
Namodenoson est actuellement en essais de phase IIb pour le traitement de la MASH, où la plupart des patients sont obèses. L'industrie mondiale du traitement de l'obésité devrait atteindre 60,5 milliards de dollars d'ici 2030, avec un taux de croissance annuel composé prévu de 22,3% entre 2025 et 2030.
Can-Fite BioPharma (NYSE American: CANF) hat angekündigt, dass das führende Arzneimittelkandidaten Namodenoson ein US-Patent als Anti-Adipositas-Medikament erhalten hat. Das Patent (Nr. 17/309,952), das 2042 abläuft, umfasst Methoden zur Behandlung von adipösen Patienten mit oral verabreichtem Namodenoson.
Das Medikament hat seine Wirksamkeit unter Beweis gestellt, indem es die Fettwerte durch die gesteigerte Produktion des Adiponektin-Hormons senkt und eine Gewichtsreduktion in tierexperimentellen Modellen der Adipositas zeigte. In einer Phase-IIa-MASH-Studie erlebten Patienten, die mit Namodenoson behandelt wurden, nach 3 Monaten eine Gewichtsreduktion von 2,3% mit signifikanten Anstiegen der Adiponektin-Spiegel.
Namodenoson befindet sich derzeit in Phase-IIb-Studien zur Behandlung von MASH, in denen die meisten Patienten übergewichtig sind. Es wird prognostiziert, dass die globale Adipositasbehandlungsindustrie bis 2030 60,5 Milliarden Dollar erreichen wird, mit einer erwarteten jährlichen Wachstumsrate von 22,3% von 2025 bis 2030.
- Patent protection secured until 2042 for anti-obesity treatment
- Demonstrated 2.3% weight loss in Phase IIa MASH study
- Favorable safety profile in clinical studies
- Multiple approved patents across different territories
- Targeting obesity market projected to reach $60.5B by 2030
- Weight loss results (2.3%) are relatively modest
- Still in early clinical development phase for obesity indication
Insights
The US Patent Office's grant for Namodenoson's use as an anti-obesity treatment marks a strategic expansion of Can-Fite's intellectual property portfolio, with protection extending to 2042. This development is particularly significant for three key reasons:
- The patent leverages existing safety data from multiple clinical trials, potentially accelerating the pathway to obesity indication approval
- The drug's unique mechanism targeting adiponectin regulation differentiates it from current market leaders like GLP-1 agonists, potentially offering a complementary or alternative treatment approach
- The timing aligns with the projected
$60.5 billion obesity market by 2030, with an impressive22.3% CAGR
The preliminary data showing
The ongoing Phase IIb MASH study will be important in validating these effects in a larger patient population. If successful, Can-Fite could potentially fast-track development for obesity indication through a supplemental application, leveraging existing safety data and reducing development costs and timelines.
The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile
Ramat Gan, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US patent office. Namodenoson is currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), advanced liver cancer and pancreatic cancer. In all clinical studies that have been conducted, Namodenoson had a very favorable safety profile when administered orally.
The patent application No. 17/309,952 entitled “An A3 adenosine receptor ligand for use for achieving a fat loss effect”, has been accepted by the US Patent Office, will be issued on February 2nd and expires in 2042.
The patent application covers methods of treating obese patients by administering Namodenoson in an oral formulation. Can-Fite has already multiple approved patents and corresponding applications in a variety of territories around the world, for different clinical applications of the drug.
The anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental animal model of obesity, induced by high fat diet. In a MASH Phase IIa study, in patients treated with Namodenoson, a
”We are delighted that the product protection of Namodenoson in the area of obesity has been accepted in the US and will be valid till 2042. Namodenoson is currently being developed for the treatment of MASH in a Phase IIb study where most patients are obese. We look forward to seeing the anti-obesity effect in this clinical study”, said Motti Farbstein, Can-Fite CE&CFO.
The obesity treatment industry worldwide is expected to reach a projected revenue of US
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), and in a Phase IIa study in pancreatic cancer. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 28, 2024 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
FAQ
What is the expiration date of Can-Fite's (CANF) new US patent for Namodenoson?
What weight loss results did Namodenoson (CANF) show in the Phase IIa MASH study?
What is the projected market size for obesity treatment that CANF is targeting?
How does Namodenoson (CANF) work to reduce fat levels?
What phase of clinical trials is CANF's Namodenoson currently in for MASH treatment?
